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For much of human history, therapies for various ailments came
about from astute phenotypic observations and serendipity [31]. For in-
stance, the origins of digoxin, a cardiac glycoside currently in use for
heart failure, can be traced directly to a traditional herbal remedy for
dropsy made from the foxglove plant [37]. With the advent of modernl of Medicine, 2220 Pierce Ave.,
ong).
Research Network of Computationabiochemistry andmolecular biology, drug discovery became dependent
on the target-based approach to systematically screen for thousands
and even millions of agents that modulate a particular biological target
chosen based on a rational therapeutic hypothesis. In the decades that
followed, an unprecedented number of new therapeutics have
transformed modern medicine and pharmaceutical industry [21].
However, despite the disproportionate focus and funding on target
based approaches for the past two decades, the pharmaceutical industry
as a whole delivered fewer “ﬁrst-in-class” drugs using this approach
than using a phenotypic approach [56]. In fact, the cost, and the risks,
of developing a new pharmaceutical entity have skyrocketed in thel and Structural Biotechnology. This is an open access article under the CC BY license
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grow exponentially, a trend termed “Eroom's Law”, to contrast with
the Moore's Law describing exponential growth in computing power
[51]. There are a number of reasons for this alarming decline in efﬁcien-
cy of pharmaceutical development. Obvious reasons include unforeseen
off-target effects and toxic metabolites that result in deleterious effects
in humans.While late stage failure in clinical trials captures headlines, a
key reason for the sustained decline in productivity may lie in the
earliest stages of drug discovery: speciﬁcally, poor target selection. For
an industry grown around target-based discovery, picking a wrong
target based on an invalid therapeutic hypothesis can be a death knell,
a situation made worse by the fact that consequences might not be
apparent until signiﬁcant expenditure of time and effort. There are
numerous causes of poor target selection, but chief among them
appears to inadequate insight into human pathophysiology provided
by in vitro and preclinical models [2,70].
Given the pitfalls of target-based screening, phenotypic screening
has reemerged as an attractive alternative and complementary
approach to drug discovery. As the name implies, this approach focuses
on phenotypic perturbations – observable changes in complex biologi-
cal function caused by small molecules – to identify chemical modula-
tors of physiological or disease processes in a target-agnostic manner.
The observed phenotype results from integration of all cellular pathway
perturbations in the context of an active biological system, be it an indi-
vidual cell or an entire organism. A phenotypic screen, by deﬁnition,
identiﬁes chemotypes that affect a biologically meaningful target or tar-
gets, including key nodes responsible for integrating cell pathways and
behaviors. Importantly, since a phenotypic screen is conducted without
regard to a priori knowledge of targets, it has the potential to discover
new therapeutic targets, whichmay have greater impact at the systems
level than established targets. Moreover, in contrast to target-based
screens, a phenotypic screen permits discovery of compounds that
affect a desired outcome via engaging multiple targets in a synergistic
manner that may not have been otherwise anticipated. Indeed, recent
studies have shown that polypharmacology is not necessarily
deleterious, and that engagement of multiple targets can sometime be
more effective for treatment of certain disease [50]. While a knowledge
of the precise pharmacological target is traditionally considered
essential, although not required by the FDA, to push a drug develop-
ment forward; there is increasing willingness to be target agnostic
provided there is a compelling biological rationale and an unmet
medical need [32].
In contrast to traditional observational approaches,whichwere low-
throughput and therefore depended on serendipity, the modern
phenotypic screen combines the advantages of phenotype-based
approaches with the latest high-throughput chemical screening
capabilities. In this review, we will provide a brief overview of various
models used in phenotypic screens, with a focus on zebraﬁsh based
screens, which has emerged as a powerful in vivo model amenable to
high-throughput and high-content analyses, and a look to the future
of phenotypic screening.
2. Phenotypic screening modalities
Modalities of phenotypic screens can be broken into two compo-
nents: the biological model and the assay outputs. These two factors
must be considered prior to any screen. A number of model systems
have been used in phenotypic screening, ranging from single cells, to
organoids and whole organisms.
Cell based screens vary in scope of potential readouts from a simple
cell viability assay to complex cell behavior analyses. At the simple end
of the spectrum, most screens for potential anti-cancer agents are cell
viability assays using established cancer cell lines [53]. At the complex
end, Lum and colleagues have screened small molecules in HCT116
human colorectal cancer cells using multiplexed luciferase assays and
dot blotting to monitor multiple pathways simultaneously [25]. Byassessing multiple pathways in a quantitative manner, they were able
to collapse the cellular phenotypes elicited by individual compounds
into a “ﬁngerprint.” Traditionally, determining mechanism of action
(MOA) can be laborious, however; such an approach provides
mechanistic insights by clustering compound induced “ﬁngerprints” to
those obtained from an siRNA library [24]. Cell based screens have
also been conducted in an image based analytics paradigm. Peppard
and colleagues identiﬁed novel autophagy regulators in HeLa cells
expressing LC3 (microtubule-associated protein light chain3)-GFP
(green ﬂuorescent protein) fusion protein as an autophagy readout.
LC3 is normally cytosolic, however during autophagy is recruited to
autophagosomal membranes, which manifest as GFP granules in this
read out. When nutrient starved cells are treated with lysomotropic
agent hydroxychloroquine (HC), which inhibits the lysosome, LC3-GFP
degradation by autophagy is blocked. Using HCS imager Incell 3000, a
250,000 compound screen was conducted to identify inhibitors of the
formation of autophagosomes, which was thresholded as b4 GFP
granules [42] Notably, the authors validated this assay with
wortmannin, a known inhibitor of autophagosome formation and
used this as a positive control to set the threshold.
While most cell based screens have been conducted in established
cell lines grown in simple monolayers or suspension, investigators
have developed 3-D organoid models of tumor cells, with the aim of
developing an in vitro model that is more relevant to human tumor
biology, including the role of metabolically quiescent tumor stem cells
and the effect of hypoxia gradient within solid tumors. For instance,
Walsh and colleagues have developed a model of spheroids derived
from primary human tumors, utilizing intrinsic ﬂuorescence properties
of FAD and NADH called optical metabolic imaging (OMI). OMI has
previously been shown to serve as an early endpoint biomarker for
drug response [60]. Using this technique the authors carried out a
screen for small molecules that altered metabolic activity of tumor
spheroids [61].
In the past fewyears, human induced pluripotent stem cells (hiPSCs)
have emerged as a promising human biological platform for phenotypic
screening. Since their initial description less than a decade ago,
researchers have created iPSC models of a myriad of human diseases
using patient-derived iPSCs [58]. For example, Burkhardt and colleagues
have generated hiPSC fromALSpatients and demonstrated that neurons
differentiated from these hiPSCs exhibit TDP-43 aggregation, a patho-
logical hallmark of ALS. Using an image-based screen based on TDP-43
aggregation in neurons generated from ALS hiPSCs, they discovered
that known small molecule inhibitors of the Na+/K+ ATPase, GSK3
and CDK could ameliorate this phenotype, providing supporting not
only for prior studies that have implicated these proteins as potential
ALS therapeutic targets but also the use of patient-derived iPSCs for
drug discovery [4].
Cell based screens, while providing an inexpensive, quantitative and
high throughput platform for phenotypic screening, suffer from several
disadvantages. Despite advances in engineered tissue constructs,
cultured cells do not exist in a native biological context and lack critical
tissue interactions and paracrine factors which clearly play an
important role in vivo. Compound liabilities such as poor metabolic
stability, suboptimal bioavailability and undesirable off-target as well
as on-target effects are not recognized early on during the primary
screen. Such issues can be addressed from the startwith in vivo chemical
screening of living organisms and whole animals. Thus far, large-scale
in vivo phenotypic screens have been conducted in various model
multicellular organisms ranging from nematode such as C. elegans to
vertebrates such as zebraﬁsh.
For instance, Petraschek and colleagues have performed a small
molecule screen for compounds that affect aging in the nematode.
From this screen, they identiﬁed 60 compounds that increase
C. elegans lifespan without obvious deleterious effects. Concordant
with existing genetic models of aging, over half of the hit compounds
increased the animal's resistance to oxidative stress [71]. Importantly,
352 C.H. Williams, C.C. Hong / Computational and Structural Biotechnology Journal 14 (2016) 350–356this screen revealed a large number of candidate targets that are
conserved in humans and hence represent potential therapeutic targets
to slow aging. Of course, C. elegans is still a very simple animal organism,
with a rudimentary physiology, lacking for instance discrete circulatory
system. Moreover, C. elegans has a very short life cycle (approximately
3.5 days) and each adult hermaphrodite has precisely 959 cells, making
them less suitable for modeling certain diseases like cancer. Finally, due
to their substantial evolutionary divergence from man (Fig. 1), the
targets of small molecules identiﬁed in invertebrates like C. elegans
and Drosophila may not be conserved in man and even then the
human orthologs may have divergent functions, making phenotypic
screens using invertebrates less than ideal for drug discovery.
3. Zebraﬁsh screens
We believe that zebraﬁsh represent a “sweet spot” for large-scale
phenotypic screens in terms of biological complexity, physiologic
similarities to humans, small size and fecundity. Zebraﬁsh are also far
less costly to maintain in large numbers necessary to conduct a large-
scale screen than mammals like mice. Although zebraﬁsh have many
important physiological differences from humans, they have numerous
similarities such homologous organ systems and complex tissue
architectures. Moreover, the majority of the functional domains of
human proteins and zebraﬁsh orthologs are highly conserved; many,
if not a majority, of the small molecules discovered in zebraﬁsh screens
should have identical or closely related targets, inman. The ﬁrst proof of
principle that zebraﬁsh could be useful for a large-scale in vivo pheno-
type screen came from a study that was conducted by Peterson and col-
leagues in 2000. In this study, the authors demonstrated that zebraﬁsh
embryos can be arrayed and screened in a 96-well format, and that
small molecules which affected embryonic development and body pat-
terning could be identiﬁed based on discrete perturbations to various
anatomic structures [43]. Moreover, given the rapid development of
zebraﬁsh, which have a functional circulatory system by 24-hour post
fertilization (hpf) and free swimming larvae by 72-hpf, the timeframe
required for a phenotypic readout is similar to many cell based assays.
Sixteen years since this landmark study, dozens, if not hundreds, of
chemical screens have been carried out in zebraﬁsh [45]. The phenotyp-
ic screens can be broadly be categorized into four major types by assay
output:morphological, therapeutic, pathway and behavioral [66]. These
four categories cover themajority of assays that have been performed in
zebraﬁsh and are meant to serve as a general framework for discussion
of different assay types, rather than be comprehensive or mutually ex-
clusive. Screens for compounds that modulate a diverse range of form
and function, such as regeneration, lipid absorption and angiogenesisFig. 1. Comparison ofmodel organisms used in phenotypic screens. Commonly accepted numbe
evolutionary divergence, gene number and genome size [29]. Also listed, the evolutionary dive
(hALK2). Unit cost: approximate cost of animals needed to screen a 96-well plate of compoun
Jackson Labs. **Cost of iPSC varies signiﬁcantly depending on differentiated cell type, culture m
high (close to in vitro HTS); +++, high (up to tens of thousands compounds/week); +, low ([45], while not speciﬁcally discussed here can be considered within
the frame of the four categories.
3.1. Morphological
As the name indicates, themorphological screen involves identiﬁca-
tion of hit compounds based on their ability to cause speciﬁc and repro-
ducible morphologic deviations from normal. The main feature of the
morphology-based approach is the variable data depth of the screen,
since they are by deﬁnition multi-dimensional [66]. The screener has
the choice between obtaining “shallower data” by focusing exclusively
on a single anatomical feature to “deeper data” to detect any discernable
morphologic changes throughout the embryo. In a screen for com-
pounds that result in altered dorsoventral (DV) patterning, we used
tail length as a primary endpoint [72], since embryos with dorsalized
pattern have grossly shortened, twisted tail [33]. This single point
screen has resulted in the discovery of dorsomorphin, the ﬁrst small
molecule inhibitor of the bone morphogenetic protein (BMP) pathway
[72] as well as a Wnt pathway modulator [13]. Even when focused on
a single feature, the phenotypic screen can obtain additional informa-
tion, increasing data depth. For example, Colanesi and colleagues
performed a chemical screen looking speciﬁcally at the pigmentation
of zebraﬁsh embryo. From this simple phenotypic screen, they could
subdivide the hit compound into 10 categories based on speciﬁc pig-
mentation alterations; these included reduced numbers of iridiophores
and/ormelanophores, changes in color depth in either cell type, ectopic
numbers of chromatophores, abnormal shape of melanophores and so
on [9].
Since the zebraﬁsh embryo is transparent, the screener can simulta-
neously score for speciﬁc changes to a predeﬁned morphologic feature
and any morphologic changes in the rest of the body. We adopted this
“all comer” approach to identify a novel hedgehog pathway inhibitor
and a lysophosphatidic acid (LPA) receptor inhibitor [12,52,67,68].
Importantly, because this screening approach is unbiased with respect
to pathways and targets, it has the potential to allow discovery of
novel mechanistic insights to regulation of pathways involved in
embryonic development. Moreover, since it is open to all possible mor-
phologic perturbations, the depth of phenomic data acquired is limited
only by technology related to high-content image analysis. In addition,
morphological screens are not limited to anatomical features visible
by standard microscopy. For example, multiple groups have utilized
transgenic ﬁsh expressing ﬂuorescent markers in the endothelium to
identify compounds that perturb the vasculature [47,59]. Similarly,
others have utilized transgenic ﬁsh expressing a ﬂuorescent marker in
cardiomyocytes to screen for compounds that effect both heartrs for generation time and brood size are listed, alongwithmedia for animalmaintenance,
rgence fromman and the amino acid sequence identity to the human BMP receptor ALK2
d libraries, in triplicate. *For mice, this is the approximate cost to purchase 288 mice from
ethods and screening conditions. Relative throughput/ease of scalability: ++++, very
up to hundreds of compounds/week).
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scale screen involving in situ hybridizations to screen for compounds
that perturb expression patterns of a cell or tissuemarker. For example,
Zon and colleagues carried out an in situ hybridization-based screen to
identify small molecules, such as leﬂunomide, which affect crestin-
expressing neural crest cell development [65].
By deﬁnition, themorphology based screens are ﬂexible, compatible
with many derivations to discover small molecules that perturb many
cell types and anatomical structures. Morphologic screens also serve
as starting points for ﬁnding molecules that affect cell behaviors as
well; for example looking at the quantity and location of leukocytes or
neutrophils at a singular time point after tail resection provides infor-
mation about where those cells are located, as seen by Liu et al., and
Robertson et al. Fromhere the authors used secondary assays to identify
compounds that modulate themigration of these cells [28,49]. An obvi-
ous shortcoming of the morphology-based screen is the lack of direct
therapeutic relevance; nevertheless, the discovery of dorsomorphin by
this approach has directly contributed to new therapeutic strategies
for numerous human diseases such as heterotopic ossiﬁcation, anemia,
IBD, and cancers [15–17,39,40,62] and has spawned several ongoing
drug development programs.
3.2. Therapeutic
The therapeutic screen uses zebraﬁsh with a disease phenotype to
identify small molecules that speciﬁcally ameliorate this phenotype. In
contrast to the morphological screen in which deviations from norm
are the “hit” criteria, in this category, a return towards the normal
phenotype would be a “hit”. In the ﬁrst of such therapeutic screens in
zebraﬁsh, Peterson and colleagues used the gridlockmutant, a zebraﬁsh
model of aortic coarctation lacking normal tail circulation at 24 to 48-
hpf, to identify small molecules which restored tail circulation [44].
Similarly, Peal and colleagues used the breakdance mutant, a zebraﬁsh
model of Long QT proarrhythmic syndrome due to a mutation in the
KCNH2 potassium channel, to screen for compounds that ameliorate
the proarrhythmic phenotype. In a relatively small screen of 1200
compounds, they identiﬁed two compounds that restored normal
heart beating and therefore have potential as anti-arrhythmic agents
[41]. In addition, other human disease models, such as Duchenne
muscular dystrophy (DMD), have been successfully screened for
compounds that suppressed the disease phenotypes [20].
Therapeutic screens have been successfully carried out in non-
genetic disease models as well. Cardiomyopathy is a relatively common
serious sequela of cancer treatment with the chemotherapeutic
doxorubicin. Peterson and colleagues developed a zebraﬁsh model of
doxorubin-induced cardiomyopathy, and conducted a counter-screen
for cardioprotective compounds [27]. Of the 3000 screened compounds,
they discovered two, visnagin and diphenylurea, which protected
cardiac function without mitigating the chemotherapeutic effects. In a
similar manner, the Peterson group also screened for chemoprotectors
against cyanide poisoning, and identiﬁed four potential antidotes [34].
In a search for candidate compounds that can accelerate recovery after
acute kidney injury (AK), Cianciolo Cosentino et al. screened for small
molecules that increase proliferation of renal progenitor cells in
zebraﬁsh embryos [6]. This screen identiﬁed histone deacetylase
inhibitor methyl-4-(phenylthio)butanoate (PTBA), which enhanced
recovery after acute kidney injury [6] and reduced postinjury renal
ﬁbrosis in mice [54]. Finally, investigators have developedMycobacteri-
um marinum infection and human carcinoma xenograft models in
zebraﬁsh [19,57]. These two models allow for identiﬁcation of com-
pound that selectively kill pathogen or tumor cells without affecting
the health and viability of zebraﬁsh. The paradigm of therapeutic
screening in zebraﬁsh is attractive because of its immediate therapeutic
relevance. While such screens show promise, using the correct model
for screening is critically important to ensure the validity of the thera-
peutic target. With the ease of genetic editing through CRISPR/Cas9,this platform would be particularly well suited for monogenic diseases
with well understood pathophysiology, as zebraﬁsh based models
could be rapidly developed and screened.
3.3. Pathway
The pathway screen involves identiﬁcation of hit compounds based
on their ability to perturb the function of a speciﬁc pathway of interest.
As with other phenotypic screens, the assay is unbiased with respect to
a particular molecular target; however, it limits the scope of potential
targets as the hit must interact with a speciﬁc pathway in a measurable
manner. This modality relies on pathway-speciﬁc read outs in the
zebraﬁsh. One of the ﬁrst pathway screens in zebraﬁsh was conducted
by Molina and colleagues. In this study, the authors took advantage of
the fact that gene expression of dual speciﬁc phosphatase-6 (dusp6), a
feedback regulator of FGF (ﬁbroblast growth factor) signaling, is itself
a robust reporter of FGF pathway activations. They used a transgenic
zebraﬁsh expressing a destabilized GFP expressed under the control of
a dusp6 promoter. In this platform, the GFP ﬂuorescence intensity
provides quantitative read out of the signaling activity [30]. From this
screen, Molina and colleagues identiﬁed a compound (E)-2-
benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one (BCI),
and used chemical genetic epistasis and computational approaches to
show that the compound targeted dusp6 itself. One drawback of GFP re-
porters in zebraﬁsh is that quantiﬁcation of ﬂuorescence can be difﬁcult
given the dynamic nature of the transgene expression pattern and that
the orientation of the zebraﬁsh in a well can dramatically affect the
apparent signal intensive. To address some of these issues, in vivo
luciferase reporter ﬁsh lines have been developed [1,64].
Finally, a single assay could have a combination of morphological,
therapeutic and pathway outputs For example, in the axinmutant em-
bryos, ectopic activation of the canonicalWnt/β-catenin signaling results
in an eyeless phenotype [63], and the axinmutant phenotype can be re-
capitulated with BIO, an inhibitor of GSK3β, a key component of the β-
catenin destruction complex inhibitor. Moreover, windorphen, a canon-
ical Wnt pathway inhibitor, can rescue the eyeless phenotype in axin
mutants [13]. Using this Wnt pathway-speciﬁc morphologic phenotype
as a read out, Nishiya and colleagues conducted a chemical suppression
screen and discovered that GGTI-286, a geranylgeranyltransferase 1
(GGTase I) inhibitor, could block canonical Wnt signaling downstream
of the β-catenin destruction complex [36]. In the developing zebraﬁsh
embryo, individual pathways do not exist in isolation; therefore, a phe-
notypic screen designed to interrogate one signaling pathway may lead
to serendipitous and sometimes context speciﬁc interaction with other
pathways.
3.4. Behavioral
One of the major unmet therapeutic areas is in neuropsychiatric
diseases, forwhichmany target based drug discovery efforts have failed.
Such difﬁculties and the fact that many current neuropsychiatric
medicines trace their roots to clinical observations on neurobehavioral
effects of drugs originally intended for other indications havemotivated
investigators to consider behavioral screens to discover novel, and
hopefully physiologically relevant, neuropsychiatric drug targets. For
this, zebraﬁsh larvae seem ideal since they are amenable to high-
throughput chemical screens and they exhibit numerous complex
behaviors reminiscent of some human behaviors. In one of the ﬁrst
behavior-based chemical screen in zebraﬁsh, Rihel and colleagues
screened over 5000 compounds for modulators of restfulness or
wakefulness. This screen resulted in the identiﬁcation of 463 unique
structures that altered zebraﬁsh behavior [48]. Of these compounds,
knownmodulators of major neurotransmitters were found to recapitu-
late many of the behavioral effects observed in mammals. For example
clonidine, a α2-adrenergic receptor agonists used as a treatment for
ADHD (attention deﬁcit hyperactivity disorder) and gaining use as a
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Subsequent behavioral screens for compounds thatmodulate responses
to photic and acoustic stimuli yielded compounds that not only
modulate immediate responses to these stimuli, but alsomore complex
behaviors such as habituation [22,69]. This technology has been
expanded to a battery of tests to identify novel neuroactive compounds
with a distinct behavioral proﬁle, a “ﬁngerprint,” which can then be
used to inform mechanism of action studies [3,46]. With ongoing
advances in behavioral analysis algorithms, it may one day be possible
to screen for compounds thatmodulate increasingly complex behaviors.
Given difﬁculties in developing drugs for neuropsychiatric diseases by
targeted approaches, zebraﬁsh-based behavioral screens represent a
bold new path for this important unmetmedical need as well as oppor-
tunities to improve our understanding of animal behavior.
4. Beyond discovery
While still relatively new, the impact of zebraﬁsh-based chemical
screens has been notable. In the past decade, the rate of published
zebraﬁsh screens has risen steadily, with an average impact factor of
9.5, as of 2013 [45]. While dissemination of knowledge through the
publication of a chemical screen is the primary goal for academics, a
secondary, implicit goal is therapeutic discovery, ultimately to impact
human health. Among a number of compounds originally identiﬁed in
zebraﬁsh chemical screens with therapeutic potential, several have re-
sulted in industry partnerships for preclinical and clinical development.Fig. 2. Proposed zebraﬁsh phenotypic screens incorporating human genome–phenome informa
by electronic health record (EHR)-coupled DNA database and by human genetic diseases st
hypotheses”). To test these hypotheses, zebraﬁsh models of human genetic diseases are g
compounds which ameliorate the disease phenotypes. These compounds are then advanced
preclinical disease models. Alternatively, a target-agnostic morphology-based screen is carri
silico against human genome–phenome database to determine whether a viable therapeuti
including compound optimization and testing in appropriate preclinical disease models.For instance, Oricula Therapeutics is developing Proto-1 for prevention
of hearing loss, Novo Biosciences is developing a metalloproteinase-13
(MMP13) inhibitor for peripheral neuropathy, and La Jolla Pharmaceu-
ticals is developing BMP receptor inhibitors for ﬁbrodysplasia ossiﬁcans
progressiva (FOP) and other rare diseases. The most advanced thera-
peutic lead resulting from a zebraﬁsh screen is the PGE2 inhibitor
Prohema [38], which has shown promising results in a randomized,
controlled Phase II study of patients undergoing hematopoietic stem
cell (HSC) transplantation for the treatment of hematologic malignan-
cies [11]. Given these early successes, it seems reasonable to anticipate
that there will bemanymore therapeutic leads resulting from zebraﬁsh
chemical screens in the coming decades.
5. Next steps: Genomics and drug discovery
There are currently about 7000 known rare diseases in man, and
roughly 4000 of these have been linked to a single genetic cause
[26,55]. Some, like familial hypercholesterolemia, are fairly common,
found in 1 in 500 individuals, while other are extremely rare like
ﬁbrodysplasia ossiﬁcans progressiva (FOP), found in 1 in 2 million
individuals. Taken together, about 10% of the US population is esti-
mated to be afﬂicted with a rare disease, representing a signiﬁcant
healthcare burden [14]. Of the disease associated genes in the Online
Mendelian Inheritance in Man (OMIM) database, 82% have at least
one zebraﬁsh ortholog [18]. With the advances in genome editing
technology, such as the clustered regularly interspaced shorttion to accelerate therapeutic discovery. Human genome–phenome information provided
udies drive formulation of therapeutic hypotheses (“human biology-based therapeutic
enerated by genomic editing and employed in phenotypic screen for novel or known
for further development, including compound optimization and testing in appropriate
ed out. Subsequently, targets of hit compounds identiﬁed, and each target evaluated in
c hypothesis can be formulated. If so, these hits are advanced for further development,
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ble to generate zebraﬁsh models of virtually all human Mendelian
diseases (Fig. 2). Once a disease phenotype or a surrogate phenotype
is established in zebraﬁsh mutants, a therapeutic screen for com-
pounds that ameliorate these phenotypes should be straightforward.
With the advances in genomic sequencing technologies, the number
of ultra-rare genetic diseases is expected to increase signiﬁcantly in
the coming decade. In such a scenario, one can easily envision
harnessing the power of zebraﬁsh phenotypic screens, perhaps
using a panel of known bioactive small molecules or FDA approved
drugs, to help accelerate drug discovery and repurposing efforts for
rare genetic diseases (Fig. 2).
A unique advantage of phenotypic screens is the discovery of novel,
previously unrecognized components involved in a biological process or
a disease pathophysiology, and chemical tools to modulate them.
However, the discovery of new pharmacological targets and new
pharmacological classes by themselves do not ameliorate the most
important reason for the high rate of failure in drug development:
uncertainties associated with target selection. Based on the ﬁrst
principles, the risks associated with target selection are inherently
lower for human Mendelian conditions. For instance, the knowledge
that rare individuals lacking proprotein convertase subtilisin/kexin
type 9 (PCSK9) have better lipid proﬁles and are protected from athero-
sclerosis and myocardial infarctions was an important factor in rapid
development and approval of PCSK9 inhibitor for treatment of
hypercholesterolemia [7,8,23,73]. But the power of human genetics
need not stop with rare Mendelian conditions. At Vanderbilt University
Medical Center (VUMC), a large human DNA repository, named BioVU,
has been linked to de-identiﬁed electronic health records (EHR) within
the Synthetic Derivative (SD) database. Using BioVU as a human
genome–phenome analysis platform, a phenome-wide association
study (PheWAS) can be carried out to determine what clinical pheno-
types are associated with single nucleotide polymorphisms (SNPs) in
a given gene (Fig. 2;[10]). Using this approach, we not only identiﬁed
potential new indications of our small molecule BMP inhibitors but
also potential on-target side effects, which will be valuable for eventual
clinical trials and post-marketing surveillance (CCH, personal
communication).
How might zebraﬁsh-based phenotypic screens leverage the power
of human genetics to accelerate drug discovery? As discussed above,
zebraﬁsh models of human Mendelian genetics can be used to carry
out therapeutic screens for compounds that ameliorate the disease
phenotype (Fig. 2). Alternatively, a novel pharmacological target
identiﬁed in unbiased morphologic screens can be interrogated by
phenome–genome databases such as BioVU to determine whether
alterations in that gene are associated with a disease phenotype and/
or therapeutic effects, dramatically lowering the risks of a drug
development program(Fig. 2). If carried out on a large scale, such efforts
might dramatically accelerate drug discovery and repurposing efforts to
meet the anticipated need for targeted therapies for rare and common
diseases (Fig. 2). In summary, zebraﬁsh is a versatile platform that has
a bright future as a drug discovery tool in the Era of Personalized
Medicines.Disclosure
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